Department of Rheumatology, VU Medical Centre, Room 3A58, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands.
Clin Rheumatol. 2010 May;29(5):465-72. doi: 10.1007/s10067-009-1328-3. Epub 2009 Dec 22.
Preference for a drug formulation is important in adherence to long-term medication for chronic illnesses such as osteoporosis. We investigated the preference for and acceptability of chewable tablet containing calcium and vitamin D (Calci Chew D(3), Nycomed) compared to that of a sachet containing calcium and vitamin D(3) (Cad, Will-Pharma). This open, randomised, cross-over trial was set up to compare the preference and acceptability of two calcium plus vitamin D(3) formulations (both with 500 mg calcium and 400/440 IU vitamin D3), given twice a day in patients with osteoporosis. Preference and acceptability were assessed by means of questionnaires. Preference was determined by asking the question, which treatment the patient preferred, and acceptability was measured by scoring five variables, using rating scales. Of the 102 patients indicating a preference for a trial medication, 67% preferred the chewable tablet, 19% the sachet with calcium and vitamin D(3,) and 15% stated no preference. The significant preference for Calci Chew D(3) (p < 0.0001) was associated with higher scores for all five acceptability variables. The two formulations were tolerated equally well. A significant greater number of patients considered the chewable tablet as preferable and acceptable to the sachet, containing calcium and vitamin D(3).
Current Controlled Trials ISRCTN18822358.
在患有骨质疏松症等慢性病的患者长期服药过程中，对药物制剂的偏好是非常重要的。我们研究了咀嚼片（Calci Chew D(3)，Nycomed）和含碳酸钙和维生素 D(3)的泡腾片（Cad，Will-Pharma）这两种钙和维生素 D(3)制剂的偏好性和可接受性。该开放性、随机、交叉试验旨在比较两种钙加维生素 D(3)制剂（均含 500mg 碳酸钙和 400/440IU 维生素 D3）在骨质疏松症患者中的偏好和可接受性，每天两次服用。通过问卷调查评估偏好性和可接受性。通过询问患者更喜欢哪种治疗方法来确定偏好性，通过评分五个变量（使用评分量表）来衡量可接受性。在表示愿意接受试验药物的 102 名患者中，67%的患者更喜欢咀嚼片，19%的患者更喜欢含碳酸钙和维生素 D(3)的泡腾片，15%的患者表示没有偏好。咀嚼片明显更受欢迎（p < 0.0001），这与所有五个可接受性变量的评分较高有关。两种制剂的耐受性相当。与泡腾片相比，更多的患者认为咀嚼片更可取和可接受。
当前对照试验 ISRCTN822358。
